乌司他丁联合阿奇霉素治疗成人重症支原体肺炎的疗效观察

The curative effect observation of ulinastatin combined with azithromycin in the treatment of severe mycoplasma pneumonia in adults

目的探讨乌司他丁联合阿奇霉素治疗成人重症支原体肺炎的疗效及安全性。方法选取2009年3月至2015年4月于我院进行治疗的成人重症支原体肺炎患者58例作为研究对象,根据治疗方案的不同将其分为观察组30例及对照组28例。对照组在常规治疗以外使用红霉素进行治疗,观察组在常规治疗以外使用乌司他丁联合阿奇霉素治疗。对两组患者临床疗效及不良反应发生率进行比较。结果观察组患者治疗总有效率为96.67%,高于对照组的78.57%(P<0.05);观察组不良反应发生率为10.00%,低于对照组的39.29%(P<0.05)。结论使用乌司他丁联合阿奇霉素治疗成人重症支原体肺炎具有良好的临床效果,安全性高。

Objectire To discuss the efficacy and safety of ulinastatin combined with azithromycin in the treatment of severe mycoplasma pneumonia in adults. Methods Fifty-eight cases of adult patients with severe mycoplasma pneumonia admitted in our hospital from March 2009 to April 2015 were selected and divided into observation group （30 cases） and control group （28 cases）. The control group received erythromycin treatment on the basis of conventional treatment , while the observation group received ulinastatin combined with azithromycin on the basis of conventional treatment. The efficacy and adverse reactions were compared between the two groups. Results The total effective rate of the observation group and the control group was 96.67% and 78.57% respectively, and the total incidence rate of adverse reactions in the observation group and the control group was 10% and 39.29% respectively, the observation group was significantly superior to those of the control group （P〈0.05）. Conclusion The ulinastatin combined with azithromycin in the treatment of adult patients with severe mycoplasma pneumonia has good clinical effect which is also safety.